and Biogen's lecanemab - could give the medical community a better sense of whether Aduhelm is up to the job of slowing the ravages of Alzheimer's.
"If another independent study of a different anti-amyloid therapy shows a clear clinical benefit, it makes me much more comfortable with continued use of Aduhelm," he said. Large clinical trials of Aduhelm, known chemically as aducanumab, produced contradictory data, with one trial failing and another showing benefit. There was also a potentially serious brain swelling side effect.
"That's not to suggest that the next drug that lowers amyloid is a slam dunk or even gets approved. It may not," he said. Japan's Eisai completed enrollment last month in a pivotal 18-month study of lecanemab in symptomatic early Alzheimer's patients. The drug is also being studied in a large trial of people with evidence of amyloid in their brains who do not yet have symptoms of the disease.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
First patient receives controversial Biogen Alzheimer's drugA U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc (BIIB.O) before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. wishing him the best! imagine if this becomes a milestone in our fight against alzheimers! JonathanLanday Did they though? There’s been a lot of controversy about this approval, and three experts on the advisory panel have resigned over it.
Source: Reuters - 🏆 2. / 97 Read more »
Big insurers are mulling new ways to pay for Biogen's $56,000-per-year Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know. spoiler alert: they'll raise premiums and deductibles along with new exclusions to not pay claims
Source: BusinessInsider - 🏆 729. / 51 Read more »
Manchin Wants Biden To Oust FDA Chief Over Controversial Alzheimer’s Drug ApprovalSen. Joe Manchin says the FDA needs new leadership, after it signed off on an Alzheimer’s drug that most members of its own advisory panel questioned. good Lol...I guess Manchin has stock in a competitor.
Source: Forbes - 🏆 394. / 53 Read more »
First patient receives controversial Biogen Alzheimer's drugA U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc (BIIB.O) before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. wishing him the best! imagine if this becomes a milestone in our fight against alzheimers! JonathanLanday Did they though? There’s been a lot of controversy about this approval, and three experts on the advisory panel have resigned over it.
Source: Reuters - 🏆 2. / 97 Read more »
Orphazyme stock plunges after receiving CRL from FDA after review of NPC treatmentShares of Orphazyme A/S undefined plummeted 54.3% in premarket trading Friday, after the Denmark-based biopharmaceutical company said overnight that it... horrible
Source: MarketWatch - 🏆 3. / 97 Read more »